The Global Radiopharmaceutical Market Forecast 2017-2027 - Seite 2

• Cyclotrons
• Nuclear Reactors

Radiopharmaceuticals, by End User: 

• Hospitals
• Diagnostic Imaging Centres
• Ambulatory Surgical Centres
• Cancer Research Institutes

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 6 regional and 21 leading national markets:

• North America:
• The US
• Canada
• Latin America:
• Brazil
• Mexico
• Rest of Latin America

• Western Europe:
• Germany
• UK
• Italy
• Spain
• France
• Nordic Countries
• Benelux
• Rest of Western Europe

• Eastern Europe:
• Russia
• Poland
• Rest of Eastern Europe

• APAC:
• Japan
• China
• India
• Australia & New Zealand
• ASEAN countries
• Rest of Asia-Pacific

• MEA:
• South Africa
• GCC
• North African countries
• Rest of MEA

The report also includes profiles and historical results for some of the leading companies in the radiopharmaceutical market, with a focus on the radiopharmaceutical segment of these companies' operations.

Leading companies and the potential for market growth: 

Overall world revenue for radiopharmaceutical will surpass $5bn in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing cost of drug development and increasing need for simulation software to reduce.

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Biosimulation Market report helps you: 

In summary, our 234-page report provides you with the following knowledge:
• Revenue forecasts to 2027 for the Biosimulation market and 4 different segmentations, with forecasts for 6 Applications, 11 Radioisotopes, 2 Sources and 4 End Users - discover the industry's prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2027 for 21 of the leading national markets - US, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Poland, Russia, Japan, China, India, Australia & New Zealand, ASEAN, GCC, South Africa, Northern African Countries
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market - including company profiles and forecasts for 9 companies' biosimulation segment revenues to 2027